Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Boundless Bio
Biotech
Boundless Bio lays off 33% of staff as lead program stumbles
Boundless has pivoted to a combination of two molecules that struggled as monotherapies after seeing phase 1/2 data on its lead candidate.
Nick Paul Taylor
May 27, 2025 8:40am
J&J vet jumps to Affinia—Chutes & Ladders
Feb 7, 2025 8:30am
Boundless drops clinical-stage cancer drug, shakes up C-suite
Dec 13, 2024 7:30am
Drug shrinks tumors in mice by targeting extrachromosomal DNA
Nov 6, 2024 12:50pm
Boundless Bio makes 'modest' layoffs 5 months after $100M IPO
Aug 13, 2024 4:27am
Boundless boldly goes public with $100M IPO
Mar 28, 2024 7:10am
